Brightsurf Science News & Current Events

September 27, 2014
Brazilian Congress of Cardiology focuses on reducing obesity and increasing exercise
More than 4,000 extra wide seats were made to accommodate Brazil's increasing obese population during the World Cup this year.

Docetaxel or pemetrexed with cisplatin achieve comparable outcomes in non-squamous Lu Ca
The first direct comparison of treating non-squamous lung cancer with either pemetrexed or docetaxel in addition to cisplatin has shown that the two combinations achieve similar progression-free survival, although docetaxel was associated with more frequent adverse events.

Afatinib improves progression-free survival in head and neck cancer
The tyrosine kinase inhibitor afatinib significantly improved progression-free survival compared to methotrexate in patients with recurrent or metastatic squamous cell carcinoma of the head and neck after failure of platinum-based chemotherapy, the results of a Phase III trial show.

Cancer during pregnancy: Chemotherapy and radiotherapy are safe for babies, studies show
Children who are exposed to chemotherapy or radiotherapy while in the womb suffer no negative impacts on mental or cardiac development, international studies presented at the ESMO 2014 Congress in Madrid have shown.

French studies measure benefits of colorectal cancer screening
The introduction of biennial colorectal cancer screening in a region of France increased the rate of diagnosis of high risk pre-cancerous adenomas -- sometimes called polyps -- by 89 percent, researchers have reported at the ESMO 2014 Congress in Madrid.

Evolutionary biology: It's not just for textbooks anymore
UA scientists, including entomology expert Bruce Tabashnik, are on the leading edge of an approach to tackle global challenges in food security, emerging diseases and biodiversity loss.

Customising chemotherapy in Lu Ca: New Ph II data reported in 2 LB studies
Measuring the expression levels of an enzyme involved in DNA synthesis can help predict the response of lung cancers to certain treatments, a Korean study has shown at the ESMO 2014 Congress in Madrid.

Anamorelin improve appetite and body mass in patients with cancer anorexia-cachexia
A new drug, anamorelin, improves appetite and body mass in patients with advanced lung cancer who are suffering cancer anorexia and cachexia, according to phase III data presented at the ESMO 2014 Congress in Madrid, Spain.

Crizotinib treatment effective against ROS1-positive lung cancer
Treatment with the targeted therapy drug crizotinib effectively halted the growth of lung tumors driven by rearrangements of the ROS1 gene in a small clinical trial.

Rolapitant reduces nausea and vomiting in Phase III trial
Rolapitant reduces nausea and vomiting in patients receiving cisplatin-based chemotherapy, according to the results of a Phase III trial presented for the first time today at the ESMO 2014 Congress in Madrid, Spain.
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.